Diagnosis of preeclampsia with soluble Fms-like tyrosine kinase 1/placental growth factor ratio: an inter-assay comparison
Diagnosis of preeclampsia with soluble Fms-like tyrosine kinase 1/placental growth factor ratio: an inter-assay comparison
复制标题
DOI：
10.1016/j.jash.2014.11.008
复制
发表时间：
2015-02-01
影响因子：
--
通讯作者：
Christesen, Henrik Thybo
中科院分区：
文献类型：
--
作者：
Andersen, Louise Bjorkholt;Frederiksen-Moller, Britta;Christesen, Henrik Thybo
血管生成因子可溶性Fms-激酶1（sFlt-1）/胎盘生长因子（PlGF）比值是诊断先兆子痫的新工具。我们在常规临床环境中比较了用于sFlt-1和PlGF的KRYPTOR（BRAHMS）自动化测定与Elecsys（Roche）测定的功效。先兆子痫妇女（n = 39）被纳入诊断后不久。血压正常的对照组妊娠按胎龄配对（n = 76）。KRYPTOR检测的结果优于或上级于Elecsys（sFlt-1/PlGF曲线下面积为0.746 vs 0.735; P = 0.09;非肥胖者为0.820 vs 0.805，P = 0.047）。对于早发性先兆子痫，KRYPTOR曲线下面积增加至0.929，在截止值85处先兆子痫的特异性为100%，在截止值33处先兆子痫的灵敏度为88.9%。对于患有先兆子痫和早产或溶血、肝酶升高、血小板计数低（HELLP）综合征的妇女，KRYPTOR sFlt-1/PlGF比率多方面增加（P <0.01）。sFlt-1/PlGF比值在早发性先兆子痫、先兆子痫伴早产或HELLP以及非肥胖妇女中特别有用。(C)2015年美国高血压学会。All rights reserved.
The angiogenic factor ratio soluble Fms-kinase 1 (sFlt-1)/placental growth factor (PlGF) is a novel diagnostic tool for pre-eclampsia. We compared the efficacy of the KRYPTOR (BRAHMS) automated assays for sFlt-1 and PlGF with the Elecsys (Roche) assays in a routine clinical setting. Preeclamptic women (n = 39) were included shortly after the time of diagnosis. Normotensive control pregnancies were matched by gestational age (n = 76). The KRYPTOR assays performed comparably or superior to Elecsys (sFlt-1/PlGF area under the curve 0.746 versus 0.735; P = .09; for non obese 0.820 versus 0.805, P = .047). For early onset preeclampsia, KRYPTOR area under the curve increased to 0.929 with a 100% specificity for preeclampsia at cut off 85 and an 88.9% sensitivity for preeclampsia at cut off 33. For women with preeclampsia and preterm delivery or Hemolysis, Elevated Liver enzymes, Low Platelet count (HELLP) syndrome, the KRYPTOR sFlt-1/PlGF ratio was manifold increased (P < .01). The sFlt-1/PlGF ratio proved especially useful in early onset preeclampsia, preeclampsia with preterm delivery or HELLP, and among non obese women. (C) 2015 American Society of Hypertension. All rights reserved.